Skip to main navigation Skip to search Skip to main content

Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label, phase 3 trial

  • Sebastian Grosicki*
  • , Maryana Simonova
  • , Ivan Spicka
  • , Ludek Pour
  • , Iryrna Kriachok
  • , Maria Gavriatopoulou
  • , Halyna Pylypenko
  • , Holger W. Auner
  • , Xavier Leleu
  • , Vadim Doronin
  • , Ganna Usenko
  • , Nizar J. Bahlis
  • , Roman Hajek
  • , Reuben Benjamin
  • , Tuphan K. Dolai
  • , Dinesh K. Sinha
  • , Christopher P. Venner
  • , Mamta Garg
  • , Mercedes Gironella
  • , Artur Jurczyszyn
    • Pawel Robak, Monica Galli, Craig Wallington-Beddoe, Atanas Radinoff, Galina Salogub, Don A. Stevens, Supratik Basu, Anna M. Liberati, Hang Quach, Vesselina S. Goranova-Marinova, Jelena Bila, Eirini Katodritou, Hanna Oliynyk, Sybiryna Korenkova, Jeevan Kumar, Sundar Jagannath, Phillipe Moreau, Moshe Levy, Darrell White, Moshe E. Gatt, Thierry Facon, Maria V. Mateos, Michele Cavo, Donna Reece, Larry D. Anderson, Jean Richard Saint-Martin, Jacqueline Jeha, Anita A. Joshi, Yi Chai, Lingling Li, Vishnuvardhan Peddagali, Melina Arazy, Jatin Shah, Sharon Shacham, Michael G. Kauffman, Meletios A. Dimopoulos, Paul G. Richardson, Sosana Delimpasi
*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

309 Scopus citations

Fingerprint

Dive into the research topics of 'Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label, phase 3 trial'. Together they form a unique fingerprint.
Sort by

Pharmacology, Toxicology and Pharmaceutical Science

Keyphrases